Anti‐PDGF‐B monoclonal antibody reduces liver fibrosis development
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Aim: To evaluate the usefulness of a platelet‐derived growth factor (PDGF)‐B specific monoclonal antibody (mAb) as a therapeutic agent to treat chronic liver fibrosis. Methods: Liver fibrosis was induced in ICR mice by bile duct ligation (BDL) or BALB/c mice by weekly injection of concanavalin A (ConA) for 4 or 8 weeks. A mAb specific for mouse and human PDGF‐B chain, AbyD3263, was generated, tested in vitro and administered twice a week throughout the experimental period. Results: AbyD3263 showed neutralizing activity against mouse and human PDGF‐B chain in cell‐based assays, as measured in vitro by inhibition of phosphorylation of PDGF receptor β and proliferation of hepatic stellate cells induced by PDGF‐BB. The half life of AbyD3263 in mice exceeded 7 days and dosing of animals twice a week resulted in constant plasma levels of the mAb. Induction of liver fibrosis by BDL and ConA resulted in elevated levels of alanine aminotransferase (ALT) in plasma and hydroxyproline in the liver. Treatment with AbyD3263 did not modify ALT levels, but significantly reduced hydroxyproline content in the liver with a maximum reduction of 39% and 54% in the BDL and ConA models, respectively, compared to controls. Conclusios: Consistent with the notion that PDGF‐BB plays an important role in the progression of liver fibrosis, AbyD3263 exhibits efficacy in pre‐clinical disease models suggesting that pharmacological inhibition of PDGF‐B chain may be a therapeutic approach to treat liver fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liver fibrosis: cellular mechanisms of progression and resolution
Henderson, N. C., & Iredale, J. P. (2007) · Clinical Science · doi:10.1042/cs20060242 · Cited by 270
Grappone, C., Pinzani, M., Parola, M., Pellegrini, G., Caligiuri, A., DeFranco, R., Marra, F., Herbst, H., Alpini, G., & Milani, S. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80169-x · Cited by 133
Cited by
Mechanisms of hepatic fibrogenesis
Lee, U. E., & Friedman, S. L. (2011) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2011.02.005 · Cited by 923
Pathogenesis of liver cirrhosis
Zhou, W.-C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i23.7312 · Cited by 627
Evolving therapies for liver fibrosis
Schuppan, D., & Kim, Y. O. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66028 · Cited by 595
Novel insights into the function and dynamics of extracellular matrix in liver fibrosis
Karsdal, M. A., Manon-Jensen, T., Genovese, F., Kristensen, J. H., Nielsen, M. J., Sand, J. M. B., Hansen, N.-U. B., Bay-Jensen, A.-C., Bager, C. L., Krag, A., et al. (2015) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00447.2014 · Cited by 263
Yoshida, S., Ikenaga, N., Liu, S. B., Peng, Z.-W., Chung, J., Sverdlov, D. Y., Miyamoto, M., Kim, Y. O., Ogawa, S., Arch, R. H., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.08.038 · Cited by 164
Self-citation
Metadata
- Authors
- Ogawa, S., Ochi, T., Shimada, H., Inagaki, K., Fujita, I., Nii, A., Moffat, M. A., Katragadda, M., Violand, B. N., Arch, R. H., & Masferrer, J. L.
- Venue
- Hepatology Research
- Publisher
- Wiley
- Published
- 2010-09-28
- Volume
- 40
- Issue
- 11
- Pages
- 1128-1141
- ISSN
- 1386-6346 (ISSN-L)
- 1872-034X
- OpenAlex
- W1921041546
- Cited by
- 62
- References
- 2
- FWCI
- 3.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti‐PDGF‐B monoclonal antibody reduces liver fibrosis development. https://app.cochat.ai/papers/10.1111/j.1872-034x.2010.00718.x
- The paper
- Ogawa, S., Ochi, T., Shimada, H., Inagaki, K., Fujita, I., Nii, A., Moffat, M. A., Katragadda, M., Violand, B. N., Arch, R. H., & Masferrer, J. L. (2010). Anti‐PDGF‐B monoclonal antibody reduces liver fibrosis development. Hepatology Research. https://doi.org/10.1111/j.1872-034x.2010.00718.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.